A Study to Determine the Antiviral Activity of TMC310911 When Administered With Ritonavir in Treatment-Naive Human Immunodeficiency Virus - Type 1 (HIV-1) Infected Patients

Inclusion Criteria: * Documented human immunodeficiency virus type 1 (HIV-1) infection for at least 6 months prior to the screening date * Participant who has not been treated with a therapeutic HIV vaccine within 1 year prior to enrolment and has never been treated with an antiretroviral (ARV) medication indicated for the treatment of HIV infection or ARVs for treatment of hepatitis B-infection with anti-HIV activity * Participant agrees not to start antiretroviral therapy (ART) before the baseline visit * Able to comply with the protocol requirements and have good accessible veins * HIV-1 plasma viral load at screening visit of above 5,000 HIV-1 Ribonucleic acid copies/mL * CD4+ cell count above 200 cells/mm3 at screening Exclusion Criteria: * HIV-2 infected participants and/or participants with any active or chronic hepato-renal disease * Life expectancy of less than 6 months * Documented acute (primary) HIV-1 infection * Pre-existing protease inhibitor (PI) medication resistance * Any currently active Acquired Immunodeficiency Syndrome (AIDS) - defining illness * Any active clinically significant disease or findings during screening or medical history or physical examination that in the investigator's opinion, would compromise the outcome of the study * Any confirmed grade 3 or 4 toxicity according to the Division of AIDS (DAIDS) grading scale at screening